Mayo Clinic has developed mhealth technology to deliver clinical decision support tools, diagnostic insights and care recommendations so clinicians can make faster and more accurate diagnoses and provide continuous care to patients.

The RDMP remote diagnostics and management platform connects data with artificial intelligence (AI) algorithms and augments human decision-making within existing clinical workflows. RDMP enables event-driven medicine, providing insights in the right context, at the right time.

“The dramatically increased use of remote patient telemetry devices coupled with the rapidly accelerating development of AI and machine learning algorithms has the potential to revolutionise diagnostic medicine,” said John Halamka, president of Mayo Clinic Platform. “With RDMP, clinicians will have access to best-in-class algorithms and care protocols and will be able to serve more patients effectively in remote care settings. The platform will also enable patients to take more control of their health and make better decisions based on insights delivered directly to them.”

Mayo Clinic has launched two companies, with partners to support the RDMP.

Mayo Clinic and AI-driven health technology company Nference have formed Anumana to create and bring to market digital sensor diagnostics by applying Nference AI to Mayo’s deep repository of medical data. Anumana will focus initially on designing neural network algorithms based on billions of relevant pieces of heart health data in Mayo Clinic’s clinical data analytics platform, including raw electrocardiogram (ECG) signals, to unlock hidden biomedical knowledge and enable early detection as well as accelerate treatment of heart disease.

“Undiagnosed heart disease affects millions of Americans and people across the globe,” said Paul Friedman, chair of the department of cardiovascular medicine at Mayo Clinic in Rochester, who led the team that developed the algorithms. “For many conditions, such as a weak or thickened heart pump, or silent arrhythmias, effective evidence-based treatments exist that can prevent heart failure, stroke or death. The key is to detect the disease before symptoms develop to prevent these events from happening. The addition of AI to the ECG, a ubiquitous and inexpensive point-of-care test that is already integrated into medical workflows, makes this approach good for patients, convenient for clinicians and massively scalable.”

Murali Aravamudan, co-founder and CEO of Nference and CEO of Anumana, added: “ECGs have been read and notated manually by physicians for more than a century. Our augmented intelligence technology, in the hands of scientific and clinical experts, will enable a comprehensive translation of the language of the heart. We think of it as the Rosetta Stone for cardiac medicine.”

Mayo Clinic and Commure, a company that helps innovators accelerate delivery of health care experiences, launched Lucem Health to provide the overall platform for connecting remote patient telemetry devices with AI-enabled algorithms, including those developed by Anumana and Mayo Clinic, and for integrating diagnostic insights generated by these algorithms into clinical workflows.

Lucem’s platform collects, orchestrates and curates data from virtually any device; hosts and supports AI and ML runtime algorithms; and delivers application development frameworks and services for workflow integration.

“Lucem Health exists to help diagnostic medicine innovations see the light of day,” said Sean Cassidy, founding CEO of Lucem Health. “We are excited to work with partners like Mayo Clinic and Anumana that are reimagining how we detect and treat diseases.”

The announcement is the latest advancement in Mayo Clinic Platform’s development of an ecosystem of partners and capabilities that complement Mayo’s clinical capabilities and provide access to scalable technology. Mayo Clinic Platform is a coordinated portfolio approach to create platform ventures and leverage emerging technologies, including AI, connected health care devices and natural language processing.

Anumana completed $25.7m in series A financing led by founders Nference and Mayo Clinic along with Matrix Capital Management, Matrix Partners and NTTVC. Anumana will use the investment to fund development and commercialisation of AI-enabled ECG and multimodal algorithms for clinical care.

Lucem Health completed $6m in series A financing led by founders Mayo Clinic and Commure. Lucem Health will use the investment to build out its platform for serving AI-generated diagnostic insights to the point of care.